natgillin/translations-raw huggingface dataset:
I studie GS-US-174-0103 var der en signifikant større andel af patienterne i tenofovirdisoproxilfumarat-gruppen, der havde normaliseret ALAT og opnået tab af HBsAg ved uge 48 end i adefovirdipivoxil-gruppen (se tabel 3 nedenfor).
In study GS-US-174-0103 a significantly greater proportion of patients in the tenofovir disoproxil fumarate group than in the adefovir dipivoxil group had normalised ALT and achieved HBsAg loss at week 48 (see Table 3 below).
I studie GS-US-174-0103 var der en signifikant større andel af patienterne i tenofovirdisoproxilfumarat-gruppen, der havde normaliseret ALAT og opnået tab af HBsAg ved uge 48 end i adefovirdipivoxil-gruppen (se tabel 4 nedenfor).
In study GS-US-174-0103 a significantly greater proportion of patients in the tenofovir disoproxil fumarate group than in the adefovir dipivoxil group had normalised ALT and achieved HBsAg loss at week 48 (see Table 4 below).
I studie GS-US-174-0108 fik 45 patienter (herunder 9 patienter med lamivudin- og/eller adefovirdipivoxilresistens-mutationer ved baseline) tenofovirdisoproxilfumarat i op til 168 uger.
In study GS-US-174-0108, 45 patients (including 9 patients with lamivudine and/or adefovir dipivoxil resistance mutations at baseline) received tenofovir disoproxil fumarate for up to 168 weeks.
I studie GS-US-174-0121 fik 141 patienter med lamivudinresistens-substitutioner ved baseline tenofovirdisoproxilfumarat i op til 240 uger.
In study GS-US-174-0121, 141 patients with lamivudine resistance substitutions at baseline received tenofovir disoproxil fumarate for up to 240 weeks.
I studie GS-US-216-0114 var hyperbilirubinæmi (> 1 x ULN) almindelig: 97,7 % i cobicistat-boostet atazanavir plus emtricitabin og tenofovirdisoproxilfumarat i fastdosis-kombination-gruppen og 97,4 % i ritonavir-boostet atazanavir plus emtricitabin og tenofovirdisoproxilfumarat i fastdosis-kombination- gruppen til og med 144 ugers behandling.
In study GS-US-216-0114, hyperbilirubinaemia (> 1 x ULN) was common: 97.7% in the cobicistat- boosted atazanavir plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group, and 97.4% in the ritonavir-boosted atazanavir plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group through 144 weeks of treatment.
I studie GS-US-236-0102, modtog hiv 1-inficerede antiretroviral-naive voksne patienter behandling med Stribild én gang daglig eller fastdosiskombination af efavirenz/emtricitabin/tenofovirdisoproxilfumarat (EFV/FTC/TDF) én gang daglig.
In study GS-US-236-0102 HIV-1 infected antiretroviral treatment-naïve adult patients received once- daily treatment of Stribild or once-daily treatment of fixed-dose combination of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).
I studie GS-US-236-0103 havde 27 patienter, der blev behandlet med Stribild, hiv 1 med NNRTI- associeret K103N-substitution i revers transkriptase ved baseline, og de havde virologisk succes (82 % ved uge 144) svarende til den samlede population (78 %) og ingen nyopstået resistens over for elvitegravir, emtricitabin eller tenofovir i deres hiv 1.
In study GS-US-236-0103, 27 patients treated with Stribild had HIV-1 with the NNRTI-associated K103N substitution in reverse transcriptase at baseline and had virologic success (82% at Week 144) similar to the overall population (78%), and no emergent resistance to elvitegravir, emtricitabine, or tenofovir in their HIV-1.
I studie GS-US-236-0115 og studie GS-US-236-0121 skulle patienterne være i gang med enten deres første eller andet antiretrovirale behandlingsregime uden tidligere virologisk svigt, de måtte ikke tidligere have oplevet resistens mod de antiretrovirale indholdsstoffer i Stribild, og de skulle være supprimerede med PI+RTV eller en NNRTI i kombination med FTC/TDF (hiv 1-rna < 50 kopier/ml) i mindst seks måneder før screening.
In Study GS-US-236-0115 and Study GS-US-236-0121, patients had to be on either their first or second antiretroviral regimen with no history of virologic failure, have no current or past history of resistance to the antiretroviral components of Stribild and must have been suppressed on a PI+RTV or an NNRTI in combination with FTC/TDF (HIV-1 RNA < 50 copies/mL) for at least six months prior to screening.
I studie GS-US-236-0123 måtte patienterne kun tidligere have fået RAL i kombination med FTC/TDF som deres første antiretrovirale behandlingsregime i mindst seks måneder.
In Study GS-US-236-0123, patients had to have previously only received RAL in combination with FTC/TDF as their first antiretroviral regimen for at least six months.
I studie GS-US-264-0106 havde 4 af de 469 patienter, som skiftede fra et ritonavir-boosted proteasehæmmer-baseret program til Eviplera, hiv 1 med nedsat følsomhed for mindst et af stofferne i Eviplera til og med uge 48.
In study GS-US-264-0106, 4 of the 469 patients who switched from a ritonavir-boosted protease inhibitor-based regimen to Eviplera had HIV-1 with reduced susceptibility to at least one component of Eviplera through week 48.
I studie GS-US-292-0104 og GS-US-292-0111 blev patienterne randomiseret i forholdet 1:1 til at få enten emtricitabin 200 mg og tenofoviralafenamid 10 mg (n = 866) én gang dagligt eller emtricitabin 200 mg +tenofovirdisoproxil (som fumarat) 245 mg (n = 867) én gang dagligt, begge givet sammen med elvitegravir 150 mg + cobicistat 150 mg som en fastdosis kombinationstablet.
In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine 200 mg + tenofovir disoproxil (as fumarate) 245 mg (n = 867) once daily, both given with elvitegravir 150 mg + cobicistat 150 mg as a fixed-dose combination tablet.
I studie GS-US-292-0106 blev virkningen, sikkerheden og farmakokinetikken af emtricitabin og tenofoviralafenamid evalueret i et ublindet studie, hvor 50 hiv 1-inficerede, behandlingsnaive unge fik emtricitabin og tenofoviralafenamid (10 mg), givet sammen med elvitegravir og cobicistat som en fastdosis kombinationstablet.
In study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet.
I studie GS-US-292-0106 blev virkningen, sikkerheden og farmakokinetikken af Genvoya evalueret i et studie af hiv 1-inficerede, behandlingsnaive unge.
In study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of Genvoya were evaluated in an open-label study in HIV-1-infected, treatment-naïve adolescents.
I studie GS-US-292-0109 blev virkningen og sikkerheden af skift fra enten EFV/FTCTDF, FTC/TDF plus atazanavir (boostet med enten cobicistat eller ritonavir) eller E/C/F/TDF til E/C/F/TAF fastdosis kombinationstablet evalueret i et randomiseret, ublindet studie af virologisk supprimerede (hiv 1-rna
In study GS-US-292-0109, the efficacy and safety of switching from either EFV/FTC/TDF, FTC/TDF plus atazanavir (boosted by either cobicistat or ritonavir), or E/C/F/TDF to E/C/F/TAF FDC tablet were evaluated in a randomised, open-label study of virologically suppressed (HIV-1 RNA
I studie GS-US-292-0109 blev virkningen og sikkerheden ved skift fra enten efavirenz (EFV)/emtricitabin (FTC)/tenofovirdisoproxilfumarat (TDF), FTC/TDF plus atazanavir (boosted med enten cobicistat eller ritonavir), eller E/C/F/TDF til Genvoya evalueret i et randomiseret, ublindet studie af virologisk supprimerede (hiv 1-rna < 50 kopier/ml) hiv 1-inficerede voksne (n = 1.436).
In study GS-US-292-0109, the efficacy and safety of switching from either efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), FTC/TDF plus atazanavir (boosted by either cobicistat or ritonavir), or E/C/F/TDF to Genvoya were evaluated in a randomised, open- label study of virologically suppressed (HIV-1 RNA < 50 copies/mL) HIV-1 infected adults (n = 1,436).
I studie GS-US-292-0112 blev virkning og sikkerhed af emtricitabin og tenofoviralafenamid evalueret i et ublindet klinisk studie, hvor 242 hiv 1-inficerede patienter med let til moderat nedsat nyrefunktion (eGFRCG: 30-69 ml/min) blev skiftet til emtricitabin og tenofoviralafenamid (10 mg), givet sammen med elvitegravir og cobicistat som en fastdosis kombinationstablet.
In study GS-US-292-0112, the efficacy and safety of emtricitabine and tenofovir alafenamide were evaluated in an open-label clinical study in which 242 HIV-1 infected patients with mild to moderate renal impairment (eGFRCG: 30-69 mL/min) were switched to emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet.
I studie GS-US-299-0102 blev patienterne randomiseret i forholdet 2:1 til at få enten fastdosis kombinationen D/C/F/TAF én gang dagligt (n = 103) eller darunavir og cobicistat og emtricitabin/tenofovirdisoproxilfumarat én gang dagligt (n = 50).
In study GS-US-299-0102, patients were randomised in a 2:1 ratio to receive either fixed-dose combination D/C/F/TAF once daily (n = 103) or darunavir and cobicistat and emtricitabine/tenofovir disoproxil fumarate once daily (n = 50).
I studie GS-US-311-1089 blev virkningen og sikkerheden ved skift fra emtricitabin/tenofovirdisoproxilfumarat til Descovy, mens det tredje antiretrovirale stof blev fortsat, evalueret i et randomiseret, dobbeltblindet studie af virologisk supprimerede hiv 1-inficerede voksne (n = 663).
In study GS-US-311-1089, the efficacy and safety of switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults (n = 663).
I studie HPC3007 (PROMISE) fik patienter, der havde haft recidiv efter tidligere IFN-baseret behandling, simeprevir (150 mg én gang dagligt) + peginterferon alfa-2a + ribavirin i 12 uger efterfulgt af yderligere 12 eller 36 ugers behandling med peginterferon alfa-2a + ribavirin (se tabel 17 og 18).
In study HPC3007 (PROMISE), patients who relapsed after prior IFN-based therapy received simeprevir (150 mg once daily) + peginterferon alfa-2a + ribavirin for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa-2a + ribavirin (see tables 17 and 18).
I studie HPC3011 (RESTORE) fik patienter, der var behandlingsnaive, eller hvor tidligere peg- IFN/RBV-behandling havde fejlet, simeprevir (150 mg én gang dagligt) + peginterferon alfa-2a + ribavirin i 12 uger efterfulgt af yderligere 12 eller 36 ugers behandling med peginterferon alfa-2a + ribavirin (se tabel 17 og 18).
In study HPC3011 (RESTORE), patients who were treatment-naïve or failed prior peg-IFN/RBV therapy received simeprevir (150 mg once daily) + peginterferon alfa-2a + ribavirin for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa-2a + ribavirin (see tables 17 and 18).
I studie I blev ACR- responset vurderet efter 7 år hos 43 patienter; heraf opnåede 72% ACR 20-respons, 58% opnåede ACR 50-respons og 44% opnåede ACR 70-respons.
In study I, ACR responses were assessed at 7 years in 43 patients with 72% ACR 20 responses, 58% ACR 50 responses, and 44% ACR 70 responses.
I studie I blev ACR-responset vurderet efter 7 år hos 43 patienter; heraf opnåede 72% ACR 20-respons, 58% opnåede ACR 50- respons og 44% opnåede ACR 70-respons.
In study I, ACR responses were assessed at 7 years in 43 patients with 72% ACR 20 responses, 58% ACR 50 responses, and 44% ACR 70 responses.
I studie I, II og V sammenlignedes effekt og sikkerhed af abatacept med placebo hos patienter, der havde utilstrækkeligt respons på methotrexat, og som fortsatte med stabil methotrexatdosis.
In Studies I, II, and V the efficacy and safety of abatacept compared to placebo were assessed in patients with an inadequate response to methotrexate and who continued on their stable dose of methotrexate.
I studie I, II, III, V og VI skulle patienterne have mindst 12 ømme og 10 hævede led ved randomisering.
Studies I, II, III, V, and VI required patients to have at least 12 tender and 10 swollen joints at randomization.
I studie II opretholdt 88% af de patienter, der havde klinisk betydningsfuld forbedring ved måned 12, respons ved måned 18, og 85% opretholdt respons ved måned 24.
In Study II, among patients with clinically meaningful improvement at month 12, 88% retained the response at month 18, and 85% retained the response at month 24.
I studie II udviklede 43% af de patienter, som ikke opnåede et ACR 20-respons efter 6 måneder, ACR 20- respons efter 12 måneder.
In Study II, 43% of the patients who had not achieved an ACR 20 response at 6 months developed an ACR 20 response at 12 months.
I studie II var middel-TSS ved baseline 31,7 hos de abataceptbehandlede patienter og 33,4 hos de placebobehandlede patienter.
In Study II, the baseline median TSS was 31.7 in abatacept-treated patients and 33.4 in placebo-treated patients.
I studie IV blev 37 patienter med KOL behandlet med abatacept, og 17 med placebo.
In Study IV, there were 37 patients with COPD treated with abatacept and 17 treated with placebo.
I studie IV blev 37 patienter med KOL behandlet med intravenøst abatacept, og 17 med placebo.
In Study IV, there were 37 patients with COPD treated with intravenous abatacept and 17 treated with placebo.
I studie LYM-3002 fik 78 % af patienterne i BzmbR-CAP-armen og 61 % af patienterne i R-CHOP- armen support med kolonistimulerende faktor.
In study LYM-3002, colony stimulating factor support was given to 78% of patients in the BzmbR-CAP arm and 61% of patients in the R-CHOP arm.
I studie MCL-002 blev TLS rapporteret hos én patient i hver af de to behandlingsarme.
In study MCL-002, TLS was reported for one patient in each of the two treatment arms.
I studie MCL-002 var der samlet en tilsyneladende stigning i tidlige (inden for 20 uger) dødsfald.
In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths.
I studie MDS-003, hvor 148 patienter fik lenalidomid ved en dosis på 10 mg, bestod den primære effektanalyse af en evaluering af lenalidomid-behandlingens indvirkning på at opnå hæmatopoietisk forbedring hos personer med lav- eller intermediær-1-risiko myelodysplastisk syndrom.
In, study MDS-003, in which 148 patients received lenalidomide at a dose of 10 mg, the primary efficacy analysis consisted of an evaluation of the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk myelodysplastic syndromes.
I studie MDS-004, hvor 205 patienter blev randomiseret ligeligt til at få enten lenalidomid 10 mg, 5 mg eller placebo, bestod den primære effektanalyse af en sammenligning af de transfusionsuafhængige responsrater af armene med 10 mg og 5 mg lenalidomid versus placeboarmen (dobbeltblindet fase 16 til 52 uger og open-label op til i alt 156 uger).
In study MDS-004, in which 205 patients were equally randomised to receive lenalidomide 10 mg, 5 mg or placebo, the primary efficacy analysis consisted of a comparison of the transfusion-independence response rates of the 10 mg and 5 mg lenalidomide arms versus the placebo arm (double-blind phase 16 to 52 weeks and open-label up to a total of 156 weeks).
I studie med VPRIV blev en række andre bivirkninger også indberettet: Meget almindelige bivirkninger:
In studies with VPRIV additional side effects have also been reported: Very common side effects are:
I studie MenACWY-TT-043 blev persistensen af immunresponset vurderet 5 år efter vaccination hos unge, der tidligere var vaccineret i studie MenACWY-TT-036 (tabel 12).
In study MenACWY-TT-043, the persistence of the immune response was evaluated 5 years after vaccination in adolescents primed in study MenACWY-TT-036 (Table 12).
I studie MenACWY-TT-043 blev varigheden af immunresponset vurderet 5 år efter vaccination hos unge, der tidligere var vaccineret i studie MenACWY-TT-036 (tabel 12).
In study MenACWY-TT-043, the persistence of the immune response was evaluated 5 years after vaccination in adolescents primed in study MenACWY-TT-036 (Table 12).
I studie MenACWY-TT-088 blev varigheden af immunresponset vurderet ved rSBA og hSBA i op til 44 måneder efter vaccination hos børn i alderen 2-10 år, som var blevet vaccineret i studie MenACWY-TT-081 (tabel 9).
In study MenACWY-TT-088, the persistence of the immune response was evaluated by rSBA and hSBA up to 44 months after vaccination in children 2-10 years of age primed in study MenACWY- TT-081 (Table 9).
I studie MMY-3010 blev induktionsbehandling med bortezomib i kombination med thalidomid og dexamethason [BzTDx, n=130] sammenlignet med thalidomid-dexamethason [TDx, n=127].
In study MMY-3010 induction treatment withbortezomib combined with thalidomide and dexamethasone [BzTDx, n=130] was compared to thalidomide-dexamethasone [TDx, n=127].
I studie MV17150 blev patienter, som ikke havde responderet på tidligere behandling med pegyleret interferon alfa-2b plus ribavirin, randomiseret til 4 forskellige behandlinger:
In study MV17150, patients who were non-responders to previous therapy with pegylated interferon alfa-2b plus ribavirin were randomised to four different treatments:
I studie PALACE 1, PALACE 2 og PALACE 3 blev der vist signifikante forbedringer i helbredsrelateret livskvalitet, målt ved ændringer fra baseline i fysisk funktion (PF)-domæne af den korte formular for sundhedsundersøgelsen version 2 (short form health survey version 2, SF-36v2) samt i den funktionelle vurdering af behandling af kronisk sygdom - træthed (functional assessment of chronic illness therapy – fatigue, FACIT-fatigue)-scoringer hos patienter i behandling med apremilast sammenlignet med placebo efter uge 16 og 24.
In studies PALACE 1, PALACE 2 and PALACE 3, significant improvements were demonstrated in health- related quality of life, as measured by the changes from baseline in the physical functioning (PF) domain of the Short Form Health Survey version 2 (SF-36v2), and in the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-fatigue) scores in patients treated with apremilast compared to placebo at Weeks 16 and 24.
I studie RO-2455-404-RD blev der observeret en højere forekomst af vægttab, appetitløshed, hovedpine og depression hos patienter, der samtidig fik roflumilast og en langtidsvirkende muskarinreceptor-antagonist (LAMA) plus inhalationskortikosteroid (ICS) og langtidsvirkende 2- agonist (LABA), sammenlignet med gruppen, som kun fik samtidig behandling med roflumilast, ICS og LABA.
A higher incidence of weight decrease, decreased appetite, headache and depression was observed during Study RO-2455-404-RD in patients receiving concomitant roflumilast and long-acting muscarinic antagonists (LAMA) plus concomitant inhaled corticosteroids (ICS) and long acting B2 agonists (LABA) compared to those treated only with concomitant roflumilast, ICS and LABA.
I studie SC-I blev abatacept administreret subkutant til patienter efter en enkelt initial intravenøs dosis abatacept og herefter en gang ugentligt.
In Study SC-I, abatacept was given subcutaneously to patients after a single loading dose of intravenous abatacept and then every week thereafter.
I studie SC-I var formålet at påvise non-inferioritet i virkning og sammenlignelighed i abatacepts sikkerhed ved subkutan og intravenøs administration til forsøgspersoner med moderat til svær aktiv RA og med utilstrækkeligt respons på MTX.
In Study SC-I, the goal was to demonstrate non-inferiority of the efficacy and comparability of the safety of abatacept subcutaneous relative to intravenous administration in subjects with moderate to severely active RA and experiencing inadequate response to MTX.
I studie SC-I var subkutant (s.c.) administreret abatacept non-inferiør sammenlignet med intravenøst (i.v.) infunderet abatacept hvad angår ACR 20-respons op til 6 måneders behandling.
In Study SC-I, abatacept administered subcutaneously (SC) was non-inferior relative to intravenous (IV) infusions of abatacept with respect to ACR 20 responses up to 6 months of treatment.
I studie SC-III blev abatacept s.c. i kombination med methotrexat (MTX) og abatacept-monoterapi sammenlignet med MTX-monoterapi med hensyn til induktion af remission efter 12 måneders behandling, samt mulig opretholdelse af lægemiddelfri remission efter komplet seponering af alle lægemidler, hos voksne MTX-naive patienter med højaktiv, tidlig reumatoid artritis (gennemsnitlig DAS28-CRP på 5,4; gennemsnitlig symptomvarighed mindre end 6,7 måneder) med faktorer, der indikerer en dårlig prognose, og hurtigt progredierende sygdom (f.eks. anti-citrullinerede protein-antistoffer [ACPA+] målt ved anti-CCP2- analyse og/eller RF-positivitet og/eller lederosioner ved baseline).
In study SC-III, abatacept SC was evaluated in combination with methotrexate, or as abatacept monotherapy, and compared to MTX monotherapy in induction of remission following 12 months of treatment, and the possible maintenance of drug-free remission after complete drug withdrawal, in adult MTX-naive patients with highly active early rheumatoid arthritis (mean DAS28-CRP of 5.4; mean symptom duration less than 6.7 months) with poor prognostic factors for rapidly progressive disease (e.g. anti- citrullinated protein antibodies [ACPA+], as measured by anti-CCP2 assay, and/or RF+, baseline joint erosions).
I studie SC-III blev sammenlignelig immunogenicitet observeret hos patienter i behandling med abatacept+MTX og abatacept-monoterapi (henholdsvis 2,9% (3/103) og 5,0% (5/101)) i løbet af den dobbeltblinde 12 måneders periode.
In Study SC-III, similar immunogenicity rates were seen in patients on treatment for the abatacept+MTX, and abatacept monotherapy groups (2.9% (3/103) and 5.0% (5/101), respectively) during the double-blind 12 month period.
I studie SC-III vurderedes strukturel ledskade ved MR-scanning.
In Study SC-III, structural joint damage was assessed by MRI.
I studie UC-II resulterede behandling med adalimumab i forbedringer i score i det tarmsygdoms- specifikke -spørgeskema (IBDQ).
In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease Questionnaire (IBDQ) score.
I studie V59P13E1 blev persistensen af immunresponset mod serogruppe A, C, W135 og Y vurderet 21 måneder, 3 år og 5 år efter primær vaccination hos forsøgspersoner i alderen 11-18 år på vaccinationstidspunktet.
In study V59P13E1, the persistence of immune responses against serogroups A, C, W135 and Y was assessed at 21 months, 3 years and 5 years post primary vaccination among subjects aged 11-18 years at the time of vaccination.
I Studie V87P11 tyder MN-resultater mod homolog A/H5N1/turkey/Turkey/1/05 på en seroprotektions- og serokonverteringsrate på henholdsvis 68 % (59-75) og 81 % (74-87).
In Study V87P11 MN results against homologous A/H5N1/turkey/Turkey/1/05 indicate a seroprotection and seroconversion rate of 68% (59-75) and 81% (74-87), respectively.
I Studie V87P11 tyder MN-resultater mod homolog A/H5N1/turkey/Turkey/1/05 på en seroprotektions- og serokonverteringsrate på henholdsvis 85 % (79-90) og 93 % (89-96).
In Study V87P11 MN results against homologous A/H5N1/turkey/Turkey/1/05 indicate a seroprotection and seroconversion rate of 85% (79-90) and 93% (89-96), respectively.
I studie VI blev ACR-responset vurderet efter 2 år hos 232 patienter; heraf opnåede 85% ACR 20- respons, 74% opnåede ACR 50-respons, og 54% opnåede ACR 70-respons.
tudy VI, ACR responses were assessed at 2 years in 232 patients with 85% ACR 20 responses, 74% ACR 50 responses, and 54% ACR 70 responses.